Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr 3;61(4):2201569.
doi: 10.1183/13993003.01569-2022. Print 2023 Apr.

New perspectives on respiratory syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic

Anne C Teirlinck  1 , Caroline K Johannesen  2   3 , Eeva K Broberg  4 , Pasi Penttinen  4 , Harry Campbell  5 , Harish Nair  5 , Rachel M Reeves  6 , Håkon Bøås  7 , Mia Brytting  8 , Wei Cai  9 , AnnaSara Carnahan  8 , Jean-Sebastien Casalegno  10 , Kostas Danis  4 , Cillian De Gascun  11 , Joanna Ellis  12 , Hanne-Dorthe Emborg  2 , Manuel Gijon  13 , Raquel Guiomar  14 , Siddhivinayak S Hirve  15 , Helena Jiřincová  16 , Hanna Nohynek  17 , Jesus Angel Oliva  18 , Richard Osei-Yeboah  5 , John Paget  19 , Gatis Pakarna  20 , Richard Pebody  21 , Lance Presser  22 , Marie Rapp  8 , Janine Reiche  9 , Ana Paula Rodrigues  14 , Elina Seppälä  7 , Maja Socan  23 , Karol Szymanski  24 , Ramona Trebbien  2 , Jaromíra Večeřová  16 , Sylvie van der Werf  25 , Maria Zambon  12 , Adam Meijer  22 , Thea K Fischer  2   3
Affiliations
Editorial

New perspectives on respiratory syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic

Anne C Teirlinck et al. Eur Respir J. .

Abstract

Learning from the COVID-19 pandemic and considering the effects of this pandemic, we provide recommendations that can guide towards sustainable RSV surveillance with the potential to be integrated into the broader perspective of respiratory surveillance. https://bit.ly/40TsO0G

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The content of the workshop on RSV surveillance was organised by SSI, RIVM and ECDC. This workshop was organised as an element of the Respiratory Syncytial Virus Consortium in Europe (RESCEU). RESCEU has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 116019. This Joint Undertaking receives support from the EU's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. This workshop was only attended by publicly funded participants of academic and public health bodies. No industrial partners participated in the meeting or were involved in writing this manuscript. The institutions of the following co-authors are partners in RESCEU: National Institute for Public Health and the Environment, RIVM, the Netherlands (A.C. Teirlinck, A. Meijer, L. Presser); Statens Serum Institute, SSI, Denmark (T.K. Fischer, R. Trebbien, H-D. Emborg and C.K. Johannesen); University of Edinburgh (H. Nair, H. Campbell, R. Osei-Yeboah); PENTA (M. Gijjon). The institutions of the following co-authors are affiliated partners in RESCEU: Norwegian Institute of Public Health (H. Bøås, E. Seppälä); Nivel, the Netherlands (J. Paget), Finnish Institute for Health and Welfare THL (H. Nohynek). E.K. Broberg and P. Penttinen (both ECDC) are members of the Scientific Advisory Group of RESCEU. H. Nohynek reports grants from GSK, Sanofi-Pasteur and Pfizer (to their institute THL, not their unit), outside the submitted work; and membership of the ESWI Scientific Committee. In addition, H. Nohynek has participated on data safety monitoring boards related to COVID-19 and Pertussis vaccines. J. Paget reports unrestricted research grants from Sanofi Pasteur, WHO, and Foundation for Influenza Epidemiology to Nivel, outside the submitted work. A.P. Rodrigues reports grants from AstraZeneca and Sanofi-Pasteur, and travel support from AstraZeneca, outside the submitted work. H. Nair reports grants from IMI, NIHR, WHO and Pfizer, consulting fees from BMGF, honoraria from AstraZeneca (all to their institute) and participated in DSM boards/advisory boards for Sanofi, ReViral, Novavax and GSK outside the submitted work. H. Campbell reports grants from EU IMI to the University of Edinburgh during the conduct of the study. H. Campbell also reports grants, consulting fees and travel support from WHO, BMGF and Sanofi (all paid via the University of Edinburgh). R.M. Reeves reports employment by IQVIA Real-World Solutions, and honoraria for manuscript writing from Sanofi Pasteur, both outside the submitted work. S. van der Werf reports a grant from Sanofi Pasteur, patents and participation in data safety monitoring boards and advisory boards, all outside the submitted work. C. De Gascun reports lecture honoraria from Sanofi-Aventis Ireland Limited, outside the submitted work. All other authors report no conflicts of interest outside the submitted work.

References

    1. van Summeren J, Meijer A, Aspelund G, et al. . Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? Euro Surveill 2021; 26: 2100639. doi:10.2807/1560-7917.ES.2021.26.29.2100639 - DOI - PMC - PubMed
    1. World Health Organization . End-to-end Integration of SARS-CoV-2 and Influenza Sentinel Surveillance: Revised Interim Guidance. WHO/2019-nCoV/Integrated_sentinel_surveillance/2022.1. Geneva, WHO, 2022.
    1. World Health Organization . Maintaining Surveillance of Influenza and Monitoring SARS-CoV-2 – Adapting Global Influenza Surveillance and Response System (GISRS) and Sentinel Systems during the COVID-19 Pandemic. WHO/2019-nCoV/Adapting_GISRS/2020.1. Geneva, WHO, 2020.
    1. Oh DY, Buda S, Biere B, et al. . Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January–September 2020: analysis of national surveillance data. Lancet Reg Health Eur 2021; 6: 100112. doi:10.1016/j.lanepe.2021.100112 - DOI - PMC - PubMed
    1. World Health Organization Regional Office for Europe . Strategy Considerations for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Other Respiratory Viruses in the WHO European Region during Autumn and Winter 2022/23: Protecting the Vulnerable with Agility, Efficiency, and Trust. WHO/EURO:2022-5851-45616-65461. Copenhagen, WHO Regional Office for Europe, 2022.

Publication types

MeSH terms